Nutritional reference points used by the NIH place deficiency risk below 12 ng/mL of total 25(OH)D, a generally inadequate status from 12 to under 20 ng/mL, and a generally adequate status from 20 ng/mL. Singular uses 20 to 50 ng/mL (50-125 nmol/L) as its internal longevity-oriented target. This target is an indirect synthesis of those reference points, an observational mortality plateau, and upper-bound caution: no paper publishes this interval as an optimum, and no causality has been demonstrated.
A randomized VITAL substudy published in 2025 in the American Journal of Clinical Nutrition observed a difference in leukocyte telomere attrition with vitamin D3 (PubMed ). This signal concerns an intermediate endpoint in a subsample; it does not turn Singular's target into a clinical threshold or geroprotective proof.
This internal target is an indirect synthesis of nutritional reference points, observational associations, and upper-bound caution. It is neither a consensus nor evidence that reaching the interval causally improves longevity.
From nutritional reference points to Singular's target
The NASEM reference points used by the NIH ODS state that a concentration below 12 ng/mL is associated with deficiency risk, 12 to under 20 ng/mL is generally inadequate, and at least 20 ng/mL is generally adequate for most people. They do not define a longevity target. In 2024, the Endocrine Society also withdrew its former general target of 30 ng/mL for the generally healthy populations it assessed.
Roger Bouillon's 2019 review in Endocrine Reviews distinguishes established skeletal actions from extra-skeletal mechanisms and still-uncertain clinical outcomes (PubMed ). A plausible cellular mechanism is not enough to set a serum target or demonstrate a benefit on mortality, cancer, or cardiovascular events.
A result of 32 ng/mL lies within Singular's 20 to 50 ng/mL target. It is neither a lower bound to exceed nor an individual optimum: no evidence shows that pushing this result toward 40 or 50 ng/mL would be beneficial.
The observational plateau: what meta-analyses show
The dose-response meta-analysis published by Garland and colleagues in the American Journal of Public Health in 2014 synthesized 32 prospective studies, totaling more than 566,000 participants (PubMed ). Observed mortality was nearly twice as high between 0 and 9 ng/mL as in the category above 30 ng/mL. This observational comparison remains exposed to confounding and reverse causality; it does not construct an individual target.
The Danish CopD cohort, published in the Journal of Clinical Endocrinology & Metabolism in 2012 by Durup and colleagues, describes a reverse J-shaped curve in 247,574 people seen in Copenhagen general practice (PubMed ). Minimum mortality was observed between 50 and 60 nmol/L (20 to 24 ng/mL); below 10 nmol/L, relative risk was 2.13, and above 140 nmol/L (56 ng/mL), it increased by 42%. These values describe this clinical cohort and are not causal or universal boundaries.
| Serum 25(OH)D status | Concentration | Longevity implication |
|---|---|---|
| Very low | ≤ 30 nmol/L (≤ 12 ng/mL) | Deficiency-risk reference point; not a diagnosis on its own |
| Low | > 30 to 50 nmol/L (> 12 to 20 ng/mL) | Generally inadequate status under nutritional reference points |
| Optimal, Singular target | > 50 to 125 nmol/L (> 20 to 50 ng/mL) | Indirect internal synthesis, with no consensus or demonstrated causal benefit |
| High | > 125 to 150 nmol/L (> 50 to 60 ng/mL) | Precautionary zone; does not mean certain toxicity |
| Very high | > 150 nmol/L (> 60 ng/mL) | Above the upper precautionary bound; toxic manifestations typically occur much higher, often > 150 ng/mL |
These nonlinear associations remind us that “more” is not necessarily “better.” They do not, however, establish that causally moving every person into a given interval reduces mortality.
VITAL 2025: an intermediate telomere signal
The VITAL trial (VITamin D and OmegA-3 TriaL) randomized 25,871 American adults (women ≥ 55 years, men ≥ 50 years) to either 2,000 IU/day of vitamin D3 or placebo, with a median follow-up of 5.3 years. The initial publication in the New England Journal of Medicine found no significant effect on its primary endpoints, invasive cancer and major cardiovascular events (PubMed ). It does not support systematic supplementation for those outcomes.
The prespecified telomere substudy published in May 2025 in the American Journal of Clinical Nutrition involved 1,054 participants with measurements at baseline and four years (PubMed ). The difference in attrition favoring D3 was 0.14 kb (95% CI: 0.007-0.27). This small subsample and intermediate endpoint demonstrate neither globally slower aging nor a clinical benefit.
The D-Health counterpoint prevents this from becoming geroprotective proof: in another randomized substudy of 1,519 older adults, telomere length did not differ between monthly vitamin D and placebo (adjusted difference −0.001; 95% CI: −0.02 to 0.02) (PubMed ). The two trials used different regimens and measurements; together, they call for treating the VITAL signal as an intermediate observation that needs confirmation.
The plateau and the J-curve: why "more" is not "better"
Toxic manifestations with hypercalcemia typically occur at very high 25(OH)D levels, often above 150 ng/mL, but an isolated value does not establish a diagnosis. A retrospective series by McCullough and colleagues reported the experience of hospitalized patients receiving 5,000 to 50,000 IU/day without cases of hypercalcemia attributed to vitamin D (PubMed ). This nonrandomized design establishes neither the general safety nor the benefit of such doses.
The CopD cohort observed rising mortality above 56 ng/mL without being able to establish causality. In the European meta-analysis of 26,916 people, no significant mortality variation was observed between 50 and 125 nmol/L (20-50 ng/mL), with very few participants at high values (PubMed ). This broad observational plateau contributes to Singular's synthesis; it does not prove that its upper boundary is the last “safe” value.
The mode of administration matters when interpreting trials. A narrative review by Mazess, Bischoff-Ferrari, and Dawson-Hughes summarized evidence on bolus dosing (PubMed ). Several trials in older adults have reported more falls or fractures after large intermittent doses. This supports caution with large boluses without demonstrating universal cellular saturation or showing that daily dosing by itself provides extra-skeletal benefits.
There is therefore no universal daily rule “for longevity.” Singular's formula applies its grid to the current result and then applies exclusions and caps; high-dose medical regimens remain outside this service policy.
Three sources of vitamin D: ultraviolet, diet, supplementation
Vitamin D is distinctive because UVB radiation (290-315 nm) triggers cutaneous synthesis. Its magnitude varies widely with latitude, season, time, exposed surface area, skin phototype, age, and protective behaviors. Exposure duration therefore cannot be reliably converted into a supplement dose, and this pathway does not justify seeking unprotected exposure.
At the latitudes of continental France, cutaneous synthesis generally decreases in winter, while its effective duration varies with location, weather, and behavior. Season remains useful context for understanding a measured result; by itself, it triggers neither winter supplementation nor an automatic dose adjustment at Singular.
Dietary intake compensates poorly for this insufficiency. Naturally rich sources are scarce: 100 g of wild salmon delivers about 600 to 800 IU, herring reaches 1,600 IU, and cod liver oil exceeds 1,300 IU per teaspoon. Egg yolk, beef liver, and UV-exposed mushrooms provide only 30 to 60 IU per serving. The INCA3 survey conducted by ANSES estimates the average dietary intake of the French adult population at 120-150 IU per day, or 15 to 20% of the official recommendation.
Unlike the United States, Finland, or Canada, France does not systematically fortify milk or cereals with vitamin D. This regulatory difference partly explains why the prevalence of vitamin D insufficiency reaches 70 to 80% of the French adult population at the end of winter, compared with 25 to 35% in the United States according to NHANES data.
| Source | Vitamin D intake | Practical limit |
|---|---|---|
| Cutaneous synthesis | Highly variable, not convertible into a dose per minute | Context-dependent; skin risk limits deliberate exposure |
| Cod liver oil | 1,360 IU / teaspoon | Low organoleptic tolerance |
| Wild salmon (100 g) | 600-800 IU | Cost and consumption frequency |
| Herring (100 g) | 1,600 IU | Same |
| Egg yolk | 30-50 IU | Marginal contribution |
| Fortified milk (United States) | 100 IU / 250 mL | Not commercialized in France |
| Singular formula (D3) | 600-2,800 IU according to the current result, or no D3 | Service grid before exclusions and caps; not a universal prescription |
Special cases: why the same dose does not produce the same level
Standardized vitamin D supplementation masks considerable interindividual variability in achieved serum levels. Understanding the factors that modulate this response avoids the pitfall of the one-size-fits-all dose.
Overweight and obesity. Lower concentrations are often observed with obesity, with distribution and dilution mechanisms discussed in Bouillon's review (PubMed ). This context helps explain variability, but Singular applies no automatic BMI multiplier: the biological tier depends on the current result.
Skin pigmentation. Melanin reduces cutaneous vitamin D production for the same UVB exposure, with variable magnitude. Skin phototype remains contextual information; it determines neither a deficiency diagnosis nor an automatic supplement when a 25(OH)D result is available.
Aging. Cutaneous synthesis capacity tends to decline with age alongside changes in exposure and health. These factors may warrant clinical evaluation in some situations, but age adds no automatic dose to Singular's current-result grid.
Pregnancy and breastfeeding. This context requires specialized recommendations and follow-up. It does not translate into an automatic adjustment of the general grid based on the biomarker alone.
Chronic kidney disease. Reduced renal 1-alpha-hydroxylase activity changes vitamin D metabolism. Advanced stages and any use of active forms require nephrology care; the general classification and product grid should not be extrapolated automatically. This context connects with the limits discussed in our article on creatinine.
Medications and chronic diseases. Some treatments and conditions alter vitamin D metabolism or the safety of supplementation. They call for clinical assessment and suitable exclusions, not an automatic increase inferred from the biomarker alone.
This heterogeneity explains why one dose cannot predict the level achieved. When the current result is available, it already integrates part of these influences; season, age, skin phototype, and history remain contextual and are not added as automatic multipliers.
Measuring your level: seasonal variability and dosage choice
When testing is indicated, total 25(OH)D—the sum of 25(OH)D2 and 25(OH)D3—is the main marker of vitamin D status. It integrates cutaneous synthesis, diet, and supplementation over several weeks. The active form 1,25(OH)₂D has specialized indications and is not the routine nutritional-status marker.
Automated immunoassays and liquid chromatography-tandem mass spectrometry do not respond identically to every form. The CDC reference procedure measures D2 and D3 separately and then adds them, while the VDSCP certifies specific platform-method combinations. D2 recovery, the C3 epimer, calibrators, and specimen matrix limit comparability: changing laboratory or method can shift a result without an equivalent biological change.
Season can shift 25(OH)D, but its magnitude and timing vary with latitude, skin phototype, exposure, diet, and supplementation. Sampling date therefore helps interpret a result; it does not require end-of-winter testing, paired summer-winter tests, or an automatic seasonal dose.
In Singular's service, a first check is proposed about three months after starting or changing a formula, then approximately every six months. This overall follow-up cadence is neither a universal medical requirement specific to VITD nor systematic seasonal screening. The indication, reimbursement, and clinical frequency of testing remain matters to assess with a healthcare professional.
Cofactors and mode of administration: what science has settled
Magnesium participates in steps of vitamin D metabolism. A 2018 review describes these mechanisms and the hypothesis that low magnesium status may limit them (PubMed ). This plausibility supports neither inferring a magnesium dose from 25(OH)D nor requiring a pretest or universal magnesium supplementation.
A 25(OH)D response that differs from expectations can have many explanations: adherence, dose, absorption, distribution, season, or analytical method. Low magnesium status is one contextual hypothesis among others, not a certain cause. This point is examined in more detail in our article on magnesium and longevity.
Vitamin K2 (as MK-7) plays a complementary role by carboxylating vitamin K-dependent proteins, including osteocalcin and matrix Gla protein. This mechanism does not show that it “directs” calcium into bone or away from arteries; long-term controlled trials do not establish an effect of the D3-K2 combination on arterial calcification. The VITD biomarker therefore triggers no K2 action.
A 2024 meta-analysis of twenty direct human comparisons concludes that D3 (cholecalciferol) raises total 25(OH)D more than D2 (ergocalciferol), with a mean difference of 10.4 nmol/L (PubMed ). This result supports the use of D3 in the formula without establishing universal superiority for a particular delivery form. As recalled in our article on the illusion of absolute dosing, a dose cannot be interpreted without the achieved result and its context.
Vitamin D illustrates the difference between population reference points and a formula policy. The former primarily describe deficiency risk and nutritional adequacy; Singular's 20 to 50 ng/mL target is a more cautious internal choice, built indirectly and without a causal promise.
The trials require separating levels of evidence: VITAL did not reduce its primary cancer and cardiovascular endpoints, and its telomere signal remains intermediate against D-Health's null result. Cohorts describe mortality associations without showing that correction toward the target improves longevity.
When a measurement is available, total 25(OH)D allows Singular to apply its grid to the current result. Without one, the formula uses its general base amount before exclusions and caps; season, level history, age group, and skin characteristics do not automatically replace the measurement.
Frequently asked questions
References
- Zhu H, Manson JE, Cook NR, et al. Vitamin D3 and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial. Am J Clin Nutr. 2025;122(1):39-47 (PubMed ).
- Bouillon R, Marcocci C, Carmeliet G, et al. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. Endocr Rev. 2019;40(4):1109-1151 (PubMed ).
- Garland CF, Kim JJ, Mohr SB, et al. Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. Am J Public Health. 2014;104(8):e43-e50 (PubMed ).
- Durup D, Jørgensen HL, Christensen J, et al. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab. 2012;97(8):2644-2652 (PubMed ).
- Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33-44 (PubMed ).
- Rahman ST, Waterhouse M, Pham H, et al. Effects of Vitamin D Supplementation on Telomere Length: An Analysis of Data from the Randomised Controlled D-Health Trial. J Nutr Health Aging. 2023;27(8):609-616 (PubMed ).
- McCullough PJ, Lehrer DS, Amend J. Daily oral dosing of vitamin D3 using 5000 TO 50,000 international units a day in long-term hospitalized patients: Insights from a seven year experience. J Steroid Biochem Mol Biol. 2019;189:228-239 (PubMed ).
- Gaksch M, Jorde R, Grimnes G, et al. Vitamin D and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium. PLoS One. 2017;12(2):e0170791 (PubMed ).
- Mazess RB, Bischoff-Ferrari HA, Dawson-Hughes B. Vitamin D: Bolus Is Bogus—A Narrative Review. JBMR Plus. 2021;5(12):e10567 (PubMed ).
- Uwitonze AM, Razzaque MS. Role of Magnesium in Vitamin D Activation and Function. J Am Osteopath Assoc. 2018;118(3):181-189 (PubMed ).
- van den Heuvel EG, Lips P, Schoonmade LJ, et al. Comparison of the Effect of Daily Vitamin D2 and Vitamin D3 Supplementation on Serum 25-Hydroxyvitamin D Concentration and Importance of Body Mass Index: A Systematic Review and Meta-Analysis. Adv Nutr. 2024;15(1):100133 (PubMed ).
